FDA
-
-
-
-
-
-
-
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
-
-
-
-
-
-
-
Prime Medicine (PRME) Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease
-
-
-
-
-
-
-
Stifel Starts Prime Medicine (PRME) at Buy
326,502 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

